P53 expression correlates with low axillary tumor burden in breast cancer.

axillary tumor burden breast cancer immunophenotypes p53

Journal

Breast disease
ISSN: 1558-1551
Titre abrégé: Breast Dis
Pays: Netherlands
ID NLM: 8801277

Informations de publication

Date de publication:
2023
Historique:
medline: 25 12 2023
pubmed: 25 12 2023
entrez: 25 12 2023
Statut: ppublish

Résumé

The p53 mutation in breast cancer confers a worse prognosis and is usually associated with p53 overexpression (p53+) on immunohistochemistry. Previous studies have shown that p53+ tumors could be associated with low axillary tumor burden (ATB). We aimed to evaluate the association between p53+ and ATB in a large series of breast cancers as an aid to personalizing axillary surgical treatment. We retrieved 1762 infiltrating breast carcinomas from our database that were treated with upfront surgery in Hospital del Mar from 2004 to 2018. We compared p53+ and p53-negative (p53-) tumors in terms of the percentage of cases with high ATB and overall survival. This comparison was made overall and for each immunophenotype. Overall, 18.7% of breast tumors were p53+. High ATB was less common in p53+ tumors than in p53- tumors in the luminal B-Her2-negative immunophenotype (6.2% versus 16.9%, respectively, P = 0.025), but not in the other immunophenotypes or overall. Overall survival was worse in patients with p53+ breast cancer (P = 0.002). p53+ breast cancers were associated with worse overall survival. However, low ATB was more common in these tumors than in p53- tumors in the luminal B-Her2-negative subtype. Information on p53 expression could be of use to predict ATB in some breast cancer tumors.

Sections du résumé

BACKGROUND BACKGROUND
The p53 mutation in breast cancer confers a worse prognosis and is usually associated with p53 overexpression (p53+) on immunohistochemistry. Previous studies have shown that p53+ tumors could be associated with low axillary tumor burden (ATB).
OBJECTIVE OBJECTIVE
We aimed to evaluate the association between p53+ and ATB in a large series of breast cancers as an aid to personalizing axillary surgical treatment.
METHODS METHODS
We retrieved 1762 infiltrating breast carcinomas from our database that were treated with upfront surgery in Hospital del Mar from 2004 to 2018. We compared p53+ and p53-negative (p53-) tumors in terms of the percentage of cases with high ATB and overall survival. This comparison was made overall and for each immunophenotype.
RESULTS RESULTS
Overall, 18.7% of breast tumors were p53+. High ATB was less common in p53+ tumors than in p53- tumors in the luminal B-Her2-negative immunophenotype (6.2% versus 16.9%, respectively, P = 0.025), but not in the other immunophenotypes or overall. Overall survival was worse in patients with p53+ breast cancer (P = 0.002).
CONCLUSION CONCLUSIONS
p53+ breast cancers were associated with worse overall survival. However, low ATB was more common in these tumors than in p53- tumors in the luminal B-Her2-negative subtype. Information on p53 expression could be of use to predict ATB in some breast cancer tumors.

Identifiants

pubmed: 38143332
pii: BD230013
doi: 10.3233/BD-230013
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

429-435

Auteurs

Pau Nicolau (P)

Breast Diseases Unit, Hospital del Mar, Barcelona, Spain.
Medicine College, Pompeu Fabra University, Barcelona, Spain.

Paula Masó (P)

Breast Diseases Unit, Hospital del Mar, Barcelona, Spain.

Núria Argudo (N)

Breast Diseases Unit, Hospital del Mar, Barcelona, Spain.
Medicine College, Pompeu Fabra University, Barcelona, Spain.

Marta Jiménez (M)

Breast Diseases Unit, Hospital del Mar, Barcelona, Spain.

Ana Isabel Martínez (AI)

Breast Diseases Unit, Hospital del Mar, Barcelona, Spain.

Ivonne Vázquez (I)

Medicine College, Pompeu Fabra University, Barcelona, Spain.
Pathology Department, Hospital del Mar, Barcelona, Spain.

Laura Comerma (L)

Medicine College, Pompeu Fabra University, Barcelona, Spain.
Pathology Department, Hospital del Mar, Barcelona, Spain.

Maria Vernet-Tomás (M)

Breast Diseases Unit, Hospital del Mar, Barcelona, Spain.
Medicine College, Pompeu Fabra University, Barcelona, Spain.

Classifications MeSH